Fan Zhang1, Yan Li2,3, Jingqiu Hu1, Jinhua Zhong1, Huafang Li4,5. 1. GlaxoSmithKline (China) R&D Company Limited, Shanghai, China. 2. Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, 4/F, 604 Lingling Road, Shanghai, 200030, China. 3. Shanghai Key Laboratory of Psychotic Disorders, Shanghai, China. 4. Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, 4/F, 604 Lingling Road, Shanghai, 200030, China. lhlh_5@163.com. 5. Shanghai Key Laboratory of Psychotic Disorders, Shanghai, China. lhlh_5@163.com.
Abstract
BACKGROUND AND OBJECTIVE: Bupropion is used for the treatment of major depressive disorder. We determined the pharmacokinetics, safety, and tolerability of extended-release bupropion XL in healthy Chinese volunteers. METHODS: This open-label, single-center pharmacokinetic study was conducted between May 2016 and June 2016. Eligible volunteers received bupropion XL 150 mg once daily for 5 days, then 300 mg once daily from days 6 to 14. Pharmacokinetic parameters were evaluated after first and repeated doses by non-compartmental and population pharmacokinetic analyses. RESULTS: Fifteen out of 16 enrolled volunteers completed the study. The geometric mean of the bupropion area under the concentration-time curve from 0 to 24 h (AUC0-24) was 498.2 and 1,165.7 h·ng/mL on days 1 and 14, respectively; maximum plasma concentration (Cmax) was 49.9 ng/mL on day 1 and steady-state maximum observed plasma concentration (Css_max) was 111.9 ng/mL on day 14. Among the three metabolites, hydroxybupropion showed the highest AUC0-24 and Cmax. The population pharmacokinetic model findings indicated an apparent oral clearance of 221 L/h for bupropion in a typical healthy 60.9-kg Chinese volunteer. CONCLUSIONS: This was the first pharmacokinetic study for bupropion XL and its active metabolites in the Chinese population. The AUC and Cmax of bupropion XL and its three metabolites increased approximately in a dose-proportional manner with an increase from 150 mg to 300 mg. Adverse events were similar to those reported in studies outside China. A population pharmacokinetic model was developed for bupropion XL, with pharmacokinetics of bupropion adequately described by a two-compartment model with first-order absorption and linear elimination plus lag time. TRIAL REGISTRATION NUMBER: NCT02698553.
BACKGROUND AND OBJECTIVE:Bupropion is used for the treatment of major depressive disorder. We determined the pharmacokinetics, safety, and tolerability of extended-release bupropion XL in healthy Chinese volunteers. METHODS: This open-label, single-center pharmacokinetic study was conducted between May 2016 and June 2016. Eligible volunteers received bupropion XL 150 mg once daily for 5 days, then 300 mg once daily from days 6 to 14. Pharmacokinetic parameters were evaluated after first and repeated doses by non-compartmental and population pharmacokinetic analyses. RESULTS: Fifteen out of 16 enrolled volunteers completed the study. The geometric mean of the bupropion area under the concentration-time curve from 0 to 24 h (AUC0-24) was 498.2 and 1,165.7 h·ng/mL on days 1 and 14, respectively; maximum plasma concentration (Cmax) was 49.9 ng/mL on day 1 and steady-state maximum observed plasma concentration (Css_max) was 111.9 ng/mL on day 14. Among the three metabolites, hydroxybupropion showed the highest AUC0-24 and Cmax. The population pharmacokinetic model findings indicated an apparent oral clearance of 221 L/h for bupropion in a typical healthy 60.9-kg Chinese volunteer. CONCLUSIONS: This was the first pharmacokinetic study for bupropion XL and its active metabolites in the Chinese population. The AUC and Cmax of bupropion XL and its three metabolites increased approximately in a dose-proportional manner with an increase from 150 mg to 300 mg. Adverse events were similar to those reported in studies outside China. A population pharmacokinetic model was developed for bupropion XL, with pharmacokinetics of bupropion adequately described by a two-compartment model with first-order absorption and linear elimination plus lag time. TRIAL REGISTRATION NUMBER: NCT02698553.
Authors: W Burleson Daviss; James M Perel; Boris Birmaher; George R Rudolph; Imad Melhem; David A Axelson; David A Brent Journal: J Am Acad Child Adolesc Psychiatry Date: 2006-12 Impact factor: 8.829
Authors: Maurizio Fava; A John Rush; Michael E Thase; Anita Clayton; Stephen M Stahl; James F Pradko; J Andrew Johnston Journal: Prim Care Companion J Clin Psychiatry Date: 2005
Authors: Anita H Clayton; Harry A Croft; Joseph P Horrigan; Donna S Wightman; Alok Krishen; Nathalie E Richard; Jack G Modell Journal: J Clin Psychiatry Date: 2006-05 Impact factor: 4.384
Authors: Jari H Stengård; Andrew G Clark; Kenneth M Weiss; Sharon Kardia; Deborah A Nickerson; Veikko Salomaa; Christian Ehnholm; Eric Boerwinkle; Charles F Sing Journal: Am J Hum Genet Date: 2002-08-05 Impact factor: 11.025
Authors: A John Rush; Madhukar H Trivedi; Stephen R Wisniewski; Andrew A Nierenberg; Jonathan W Stewart; Diane Warden; George Niederehe; Michael E Thase; Philip W Lavori; Barry D Lebowitz; Patrick J McGrath; Jerrold F Rosenbaum; Harold A Sackeim; David J Kupfer; James Luther; Maurizio Fava Journal: Am J Psychiatry Date: 2006-11 Impact factor: 18.112
Authors: Vishal Lamba; Jatinder Lamba; Kazuto Yasuda; Stephen Strom; Julio Davila; Michael L Hancock; James D Fackenthal; Peter K Rogan; Barbara Ring; Steven A Wrighton; Erin G Schuetz Journal: J Pharmacol Exp Ther Date: 2003-10-09 Impact factor: 4.030
Authors: Karen Hewett; Michelle D Gee; Alok Krishen; Hans-Peter Wunderlich; Alfred Le Clus; Gary Evoniuk; Jack G Modell Journal: J Psychopharmacol Date: 2009-11-25 Impact factor: 4.153
Authors: K Hewett; W Chrzanowski; M Schmitz; A Savela; V Milanova; M Gee; A Krishen; L Millen; M O Leary; J Modell Journal: J Psychopharmacol Date: 2008-07-17 Impact factor: 4.153
Authors: Mohamed-Eslam F Mohamed; Mukul Minocha; Sheryl Trueman; Tian Feng; Jeffrey Enejosa; Ogert Fisniku; Ahmed A Othman Journal: Clin Pharmacol Drug Dev Date: 2020-07-09